CN | EN
做好药,为生命更美好
Better Medicine for Better Life
About Us
Founded in December 2017,We are a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutic candidates to treat cancer and Nephropathy.
More
Strategy
Joint R&D for potential BIC pipeline
2017-12-28
Building a leading edge in the clinical trial system
Enhancing in-house R&D capabilities and Transforming to Global Innovation
Integrate resources to strengthen commercialization capabilities
More
News
03 2024.03
BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062
More
20 2023.12
BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial
More
15 2023.11
Riding the tide, realize the future: The BD paths for Chinese Biotech
The Interview of Dr. Kaan Certel (The CBO of BioCity)
More
27 2023.09
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
More
More
Career
We have always been adhering to the mission of "Better Medicine for Better Life", and dedicate to developing "BIC/FIC" drugs with unmet needs.
We invite like-minded you to join us to create a healing tomorrow together.
Join Us